In our study, we present data showing that metformin can act in an LKB1-AMPK-independent way to induce prostate cancer cell death and counter hyperglycaemia-induced chemoresistance and that these effects involve the regulation of IGFBP-2. This evidence concerns the gene STK11 and prostate carcinoma.